In this webcast, experts discuss the SURTAVI trial and the SAPIEN 3 study in intermediate-risk patients as well as the outcomes of TAVR and SAVR.

Learn how transcatheter therapy can benefit patients that would not normally be candidates for TAVR and the importance of including the whole heart team for optimal success.

This webcast will discuss the options available to patients and give a comprehensive review of the data from the EXCEL and NOBLE trials. Conversations will also highlight some of the varied treatments currently used in Europe and what cardiac interventionists in the United States can anticipate.